Integrating Macrogenetics and Metabolomics to Explore the Mechanisms of Differential Response to Lencanumab in Alzheimer's Disease Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500098225

Enrollment

Unknown

Registered

2025-03-04

Start date

2025-03-31

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

Observation group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Voluntary signed informed consent; (2) Patients with mild cognitive impairment due to Alzheimer's disease and mild dementia due to Alzheimer's disease.

Exclusion criteria

Exclusion criteria: (1) Patients with severe hypersensitivity, including angioedema and anaphylactic reactions, to lencanumab or any of the excipients of the product; (2) Pregnant as well as lactating women; (3) Patients with AD who are on anticoagulants; (4) AD patients with coagulation disorders; (5) AD patients with significant cerebral hemorrhage, brain swelling, aneurysm, vascular malformation, or brain tumor; (6) People with uncontrollable bleeding disorders; (7) Those who, in the judgment of the investigator, are deemed unsuitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Blood routine index;Microbiological indicator;	—

Countries

China

Contacts

Public ContactXue Man

Shenzhen Hospital of Southern Medical University

xueman0623@163.com+86 198 2960 5490

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026